Lymphoma development in a patient receiving anti-TNF therapy.
Ziakas
Panayiotis D
PD
Department of Pathophysiology, Medical School, National University of Athens, Hellas.
Giannouli
Stavroula
S
Tzioufas
Athanasios G
AG
Voulgarelis
Michalis
M
D000068879:Adalimumab; D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D001172:Arthritis, Rheumatoid / Q000628:therapy; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000175:diagnosis* / Q000209:etiology*; D008279:Magnetic Resonance Imaging; D008297:Male; D013479:Superior Vena Cava Syndrome / Q000000981:diagnostic imaging; D014057:Tomography, X-Ray Computed; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000276:immunology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab